Research Study for Women who have Complex Atypical Hyperplasia OR Stage 1a Grade 1 Endometrial Cancer

UVA Tracking #
HSR180026
Principal Investigator
Kari E Ring
Contact
Rachel Lacy
Contact Email
Contact Phone
434.243.0126
Official Trial Title
Phase II Study of the Levonorgestrel Intrauterine Device Alone or in Combination with the mTORC1 Inhibitor, Everolimus, for the Treatment of Complex Atypical Hyperplasia and Stage Ia Grade 1 Endometrial Cancer
Study Description

The UVA Cancer Center seeks women ages 18 and over who have Complex Atypical Hyperplasia OR Stage 1a Grade 1 Endometrial Cancer for a clinical trial.

The purpose of this study is to learn if the Mirena intrauterine device (levonorgestrel IUD), alone or in combination with the immunosuppressant drug, Everolimus, is effective for the treatment of endometrial hyperplasia and/or early-stage endometrial cancer. Disease response and the side effects (good and bad) of the two treatments will be studied as part of this clinical trial.

Participation includes placement of an IUD, having an electrocardiogram (EKG) and blood tests. Some participants may also take the study drug.

Being a part of this clinical trial will only require an additional 20-30 minutes to visits or procedures you are having as part of clinical care.

The study drug (Everolimus) will be provided at no cost to you.

Additional information can be found here: NCT02397083

Compensation

No Compensation